A novel drug designed to specifically target RET has shown high response rates and durable efficacy in patients with RET fusion positive lung and thyroid cancers. The results from two phase 1-2 trials of selpercatinib (formerly known as LOXO-292) just published in NEJM also show that it is well tolerated and has significant intracranial activity ...
Drug that targets RET fusion shows good responses in NSCLC and thyroid cancers
By Michael Woodhead
27 Aug 2020